StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals GTN rebate accruals by Year

GTN rebate accruals — Provision for current year product sales ($M) ($M)

Vertex Pharmaceuticals GTN rebate accruals: $3,780M in FY2025, up 2.9% from a year earlier. That is the highest of the 13 years on record here.

Latest, FY2025
3,780
Period ended Dec 31, 2025
Change on a year earlier
+2.9%
3,673 in FY2024
History
13 years
Since FY2013
Sources
11
Documents cited below

Where the FY2025 figure comes from

“|| Provision related to 2025 sales | 3,780.4”

Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗

Reported in Form 10-K MD&A (Critical Accounting Policies — Gross-to-Net Rebate Rollforward).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGTN rebate accruals — Provision for current year product sales ($M) ($M)Year on yearSource
FY2025Dec 31, 20253,780+2.9%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
FY2024Dec 31, 20243,673+5.5%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
FY2023Dec 31, 20233,481+16.9%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
FY2022Dec 31, 20222,977+40.0%Form 10-K (vrtx-20241231.htm, filed 2025-02-13) ↗
FY2021Dec 31, 20212,126+65.6%Form 10-K (vrtx-20231231.htm, filed 2024-02-15) ↗
FY2020Dec 31, 20201,284+95.7%Form 10-K (vrtx-20221231.htm, filed 2023-02-10) ↗
FY2019Dec 31, 2019656-4.1%Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
FY2018Dec 31, 2018684+286.6%Form 10-K (vrtx-20201231.htm, filed 2021-02-11) ↗
FY2017Dec 31, 2017177+31.9%Form 10-K (a201910k-main.htm, filed 2020-02-13) ↗
FY2016Dec 31, 2016134+104.0%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2015Dec 31, 201565.8+84.3%Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗
FY2014Dec 31, 201435.7-82.5%Form 10-K (a201610k-main.htm, filed 2017-02-23) ↗
FY2013Dec 31, 2013205–Form 10-K (a201510k-main.htm, filed 2016-02-16) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals GTN rebate accruals ($M), annual FY2013–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/gtn-provision-cur

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.